ANALYSIS OF AGOMELATINE TREATMENT WITH DEPRESSIVE SYMPTOMS
DOI:
https://doi.org/10.22159/ijap.2021.v13s1.Y0110Keywords:
Agomelatine, Melatonin, Insomnia, Chi-squared test, Logistic regressionAbstract
Objective: Agomelatine is a new mechanism of antidepressants, which is approved by Taiwan Food and Drug Administration and available in Taiwan.
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. The structures
of agomelatine are similar to melatonin with not only the effects to maintain depression symptoms but also can help patients who have insomnia.
Methods: This is a retrospective study. In a mental hospital in Taoyuan, we analyzed the prescriptions of the outpatients who were prescribed
agomelatine to realize the effects of agomelatine and whether the prescriptions were prescribed appropriately.
Results: Catastrophic illnesses were found to be associated with significantly used multiple hypnotics (χ2 =22.02, p<0.001). When patients’ age
increased by 1 year, multiple hypnotics used increased by 1.013 times (Exp(B)=1.013, p<0.01). Catastrophic illnesses were found to be associated
with significantly used augmentation with other antidepressants (χ2=54.07, p<0.001).
Conclusions: Doctors should be evaluating the benefits and risks when they prescribe a medicine to patients, and they should be written in medical
record. This study is the hope to provide relevant units as a reference for formulating health policies.
Downloads
References
Ogawa Y, et al. Comparative efficacy and acceptability of 21
antidepressant drugs for the acute treatment of adults with major
depressive disorder: A systematic review and network meta-analysis.
Lancet 2018;391:1357-66.
2. Li YI, Starr LR, Wray-Lake L. Insomnia mediates the longitudinal
relationship between anxiety and depressive symptoms in a nationally
representative sample of adolescents. Depress Anxiety 2018;35:583-91.
3. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive
disorder: Meta-analysis and appraisal. Int J Neuropsychopharmacol
2012;15:417-28.
4. Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M.
Agomelatine versus other antidepressive agents for major depression.
Cochrane Database Syst Rev 2013;12:CD008851.
5. Wu CY, Liang KC. Oral antidepressant-agomelatine. J Taiwan Pharm
2013;116:44-7.
6. Kennedy SH, Heun R, Avedisova A, Ahokas A, Olivier V, Picarel-
Blanchot F, et al. Effect of agomelatine 25-50 mg on functional
outcomes in patients with major depressive disorder. J Affect Disord
2018;238:122-8.
7. Freiesleben SD, Furczyk K. A systematic review of agomelatineinduced
liver injury. J Mol Psychiatry 2015;3:4.
8. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressantinduced
liver injury: A review for clinicians. Am J Psychiatry
2014;171:404-15.
9. Holshoe JM. Antidepressants and sleep. In: Reference Module in
Neuroscience and Biobehavioral Psychology. Amsterdam, Netherlands:
Elsevier; 2017.
10. Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of
antidepressants on sleep. Curr Psychiatry Rep 2017;19:63.
11. DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann
Pharmacother 2007;41:1201-11.
